Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study

Figures & data

Table 1 Patient Baseline Demographics and Clinic Pathological Characteristics (N = 31)

Baseline Characteristics	N (%)
Age, years
Median (range)	57 (25–75)
Gender
Male	25 (80.6)
Female	6 (19.4)
ECOG PS
0	15 (48.4)
1	16 (51.6)
Clinical T stage
T2	2 (6.5)
T3	17 (54.8)
T4a	12 (38.7)
Clinical N stage
N0	10 (32.3)
N1	12 (38.7)
N2	8 (25.8)
N3	1 (3.2)
cTNM staging
II	8 (25.8)
III	11 (35.5)
IVa	12 (38.7)
Position
Upper	3 (9.7)
Middle	12 (38.7)
Lower	16 (51.6)

Abbreviations: cTNM, tumor, nodes, metastasis classification of staging; ECOG PS, Eastern Cooperative Oncology Group Performance Status.

Figure 1 Patient flow diagram of this study.

Table 2 Efficacy Outcomes Post-Surgery with Neoadjuvant Chemotherapy Regimen

Variables	N (%)
Patients who received surgery after neoadjuvant chemotherapy alone (n = 21)
pCR	8/21 (38.1)
MPR	15/21 (71.4)
Patients who received surgery (n = 24)
pCR	9/24 (37.5)
MPR	16/24 (66.7)
R0 resection	23/24 (95.8)
Stage I (ypT1-2N0)	15 (62.5)
Stage II (ypT3N0)	3 (12.5)
Stage IIIA (ypT0-2N1)	4 (16.7)
Stage IIIB (ypT3N1/T0-3N2/T4a N0)	1 (8.3)
ypN0	18 (75)
ypN1	4 (16.7)
ypN2	1 (8.3)
Post-surgical morbidities	3 (12.5)
Pleural cavity infection	1 (4.2)
Pneumonia	1 (4.2)
Mediastinitis	1 (4.2)

Abbreviations: MPR, major pathological response; pCR, partial complete response.

Table 3 Adverse Events Due to Neoadjuvant Chemotherapy (N = 31)

Events	Any Grade N (%)	Grade 3 N (%)	Grade 4 N (%)
Neutropenia	23 (74.2%)	9 (29%)	2 (6.5%)
Leukopenia	21 (67.7%)	3 (9.7%)	0
Anaemia	17 (54.8%)	0	0
Thrombocytopenia	9 (29%)	0	1 (3.2%)
Elevated ALT	3 (9.7%)	1 (3.2%)	0
Nausea	22 (70.9%)	0	0
Vomiting	11 (35.5%)	0	0
Loss of appetite	12 (38.7%)	0	0
Fatigue	7 (22.6%)	0	0
Peripheral neurotoxicity	12 (38.7%)	0	0
Alopecia	15 (48.3%)	0	0
Foot-hand syndrome	6 (19.4%)	0	0

Abbreviation: ALT, alanine transaminase.